Literature DB >> 19548831

A dual-fluorescence high-throughput cell line system for probing multidrug resistance.

Kyle R Brimacombe1, Matthew D Hall, Douglas S Auld, James Inglese, Christopher P Austin, Michael M Gottesman, King-Leung Fung.   

Abstract

The efflux pump P-glycoprotein (ATP-binding cassette B1, multidrug resistance [MDR] 1, P-gp) has long been known to contribute to MDR against cancer chemotherapeutics. We describe the development of a dual-fluorescent cell line system to allow multiplexing of drug-sensitive and P-gp-mediated MDR cell lines. The parental OVCAR-8 human ovarian carcinoma cell line and the isogenic MDR NCI/ADR-RES subline, which stably expresses high levels of endogenous P-gp, were transfected to express the fluorescent proteins Discosoma sp. red fluorescent protein DsRed2 and enhanced green fluorescent protein, respectively. Co-culture conditions were defined, and fluorescent barcoding of each cell line allowed for the direct, simultaneous comparison of resistance to cytotoxic compounds in sensitive and MDR cell lines. We show that this assay system retains the phenotypes of the original lines and is suitable for multiplexing using confocal microscopy, flow cytometry, or laser scanning microplate cytometry in 1,536-well plates, enabling the high-throughput screening of large chemical libraries.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19548831      PMCID: PMC2814070          DOI: 10.1089/adt.2008.165

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  39 in total

Review 1.  The role of membrane transporters in drug delivery to brain tumors.

Authors:  Anne T Nies
Journal:  Cancer Lett       Date:  2007-01-31       Impact factor: 8.679

Review 2.  ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells.

Authors:  Brian L Abbott
Journal:  Clin Adv Hematol Oncol       Date:  2006-01

Review 3.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

4.  Interaction of imatinib mesilate with human P-glycoprotein.

Authors:  Akinobu Hamada; Hideto Miyano; Hiroshi Watanabe; Hideyuki Saito
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

5.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.

Authors:  Gergely Szakács; Jean-Philippe Annereau; Samir Lababidi; Uma Shankavaram; Angela Arciello; Kimberly J Bussey; William Reinhold; Yanping Guo; Gary D Kruh; Mark Reimers; John N Weinstein; Michael M Gottesman
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector.

Authors:  Marc van de Wetering; Irma Oving; Vanesa Muncan; Menno Tjon Pon Fong; Helen Brantjes; Dik van Leenen; Frank C P Holstege; Thijn R Brummelkamp; Reuven Agami; Hans Clevers
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

Review 7.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

8.  Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line.

Authors:  C Melguizo; J Prados; J E Fernández; C Vélez; L Alvarez; A Aránega
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1994-03       Impact factor: 1.770

9.  Karyotypic complexity of the NCI-60 drug-screening panel.

Authors:  Anna V Roschke; Giovanni Tonon; Kristen S Gehlhaus; Nicolas McTyre; Kimberly J Bussey; Samir Lababidi; Dominic A Scudiero; John N Weinstein; Ilan R Kirsch
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

10.  Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins.

Authors:  Anna Maria Calcagno; Katherine J Chewning; Chung-Pu Wu; Suresh V Ambudkar
Journal:  BMC Mol Biol       Date:  2006-09-17       Impact factor: 2.946

View more
  30 in total

1.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

2.  A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.

Authors:  Christophe Antczak; Boyoung Wee; Constantin Radu; Bhavneet Bhinder; Eric C Holland; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2013-08-30       Impact factor: 1.738

3.  Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression.

Authors:  Mar Gacias; Guillermo Gerona-Navarro; Alexander N Plotnikov; Guangtao Zhang; Lei Zeng; Jasbir Kaur; Gregory Moy; Elena Rusinova; Yoel Rodriguez; Bridget Matikainen; Adam Vincek; Jennifer Joshua; Patrizia Casaccia; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2014-06-19

4.  Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.

Authors:  Andrew S Goldsborough; Misty D Handley; Andrés E Dulcey; Kristen M Pluchino; Pavitra Kannan; Kyle R Brimacombe; Matthew D Hall; Gary Griffiths; Michael M Gottesman
Journal:  J Med Chem       Date:  2011-06-24       Impact factor: 7.446

5.  The Inhibitor Ko143 Is Not Specific for ABCG2.

Authors:  Lora D Weidner; Sami S Zoghbi; Shuiyu Lu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Jan Mulder; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  J Pharmacol Exp Ther       Date:  2015-07-06       Impact factor: 4.030

6.  Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.

Authors:  Matthew D Hall; Kyle R Brimacombe; Matthew S Varonka; Kristen M Pluchino; Julie K Monda; Jiayang Li; Martin J Walsh; Matthew B Boxer; Timothy H Warren; Henry M Fales; Michael M Gottesman
Journal:  J Med Chem       Date:  2011-08-01       Impact factor: 7.446

7.  The impact of cell density and mutations in a model of multidrug resistance in solid tumors.

Authors:  James Greene; Orit Lavi; Michael M Gottesman; Doron Levy
Journal:  Bull Math Biol       Date:  2014-02-20       Impact factor: 1.758

8.  Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin.

Authors:  Matthew D Hall; Travis S Marshall; Alexandra D T Kwit; Lisa M Miller Jenkins; Andrés E Dulcey; James P Madigan; Kristen M Pluchino; Andrew S Goldsborough; Kyle R Brimacombe; Gary L Griffiths; Michael M Gottesman
Journal:  J Biol Chem       Date:  2014-06-14       Impact factor: 5.157

9.  Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.

Authors:  Lora D Weidner; King Leung Fung; Pavitra Kannan; Janna K Moen; Jeyan S Kumar; Jan Mulder; Robert B Innis; Michael M Gottesman; Matthew D Hall
Journal:  Drug Metab Dispos       Date:  2015-12-10       Impact factor: 3.922

10.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.